Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic phosphopeptide derived from human p21Cip1 around the phosphorylation site of Thr145 (R-Q-TP-S-M)|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.4, with 50% glycerol, 150mM NaCl|
|Contains||0.02% sodium azide|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:100|
|Western Blot (WB)||1:500-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
It is now well established that cyclins play a positive role in promoting cell cycle transitions via their ability to associate with and activate their cognate cyclin-dependent kinases (Cdks). Cdk2 associates with cyclins A, D and E, and has been implicated in the control of the G1 to S phase transition in mammals. A novel Cdk-interacting protein, designated p21, Cip1 or WAF1, has been identified in cyclin A, cyclin D1, cyclin E and Cdk2 immunoprecipitates. p21 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk 2, cyclin E-Cdk2, cyclin D1-Cdk4 and cyclin D2-Cdk4 complexes. Expression of p21 is inducible by wildtype, but not mutant, p53. The mouse homolog of p21 is designated CAP20.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
CAP20; CDK-interacting protein 1; CDK-interaction protein 1; CDKN1; CDKN1A; CIP1; Cyclin-dependent kinase inhibitor 1; cyclin-dependent kinase inhibitor 1A (p21, Cip1); DNA synthesis inhibitor; MDA-6; MDA6; melanoma differentiation associated protein 6; Melanoma differentiation-associated protein 6; p21; PIC1; SDI1; WAF1; wild-type p53-activated fragment 1
CAP20; CDKN1; CDKN1A; CIP1; MDA-6; MDA6; P21; p21CIP1; PIC1; SDI1; WAF1